Browsing ICR Divisions by author "Huang, Paul"

Now showing items 21-40 of 72

    • Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. 

      Stacchiotti, S; Miah, AB; Frezza, AM; Messiou, C; Morosi, C; et al. (ELSEVIER, 2021-06-02)
      Epithelioid hemangioendothelioma (EHE) is an ultra-rare, translocated, vascular sarcoma. EHE clinical behavior is variable, ranging from that of a low-grade malignancy to that of a high-grade sarcoma and it is marked by a ...

    • Evaluation of Systemic Treatment Options for Gastrointestinal Stromal Tumours. 

      Golčić, M; Jones, RL; Huang, P; Napolitano, A (MDPI, 2023-08-13)
      Gastrointestinal stromal tumours (GIST) are the most common mesenchymal tumours of the gastrointestinal tract. Surgical treatment is recommended for the majority of localised GIST, while systemic treatment is the cornerstone ...

    • Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. 

      Vyse, S; Howitt, A; Huang, PH (ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2017-06-16)
      Despite the recent approval of third-generation therapies, overcoming resistance to epidermal growth factor receptor (EGFR) inhibitors remains a major challenge in non-small cell lung cancer. Conceptually, synthetic lethality ...

    • Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. 

      Harrison, PT; Huang, PH (PORTLAND PRESS LTD, 2018-10-26)
      Drug resistance remains one of the greatest challenges facing precision oncology today. Despite the vast array of resistance mechanisms that cancer cells employ to subvert the effects of targeted therapy, a deep understanding ...

    • Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. 

      Napolitano, A; Ostler, AE; Jones, RL; Huang, PH (MDPI, 2021-06-17)
      Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) signaling ...

    • Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. 

      Martinez, VG; Pankova, V; Krasny, L; Singh, T; Makris, S; et al. (CELL PRESS, 2019-11-26)
      Lymph nodes (LNs) act as filters, constantly sampling peripheral cues. This is facilitated by the conduit network, a tubular structure of aligned extracellular matrix (ECM) fibrils ensheathed by fibroblastic reticular cells ...

    • Functional genomic analysis of epithelioid sarcoma reveals distinct proximal and distal subtype biology. 

      Rasmussen, SV; Jin, JX; Bickford, LR; Woods, AD; Sahm, F; et al. (JOHN WILEY & SONS LTD, 2022-07-01)
      BACKGROUND: Metastatic epithelioid sarcoma (EPS) remains a largely unmet clinical need in children, adolescents and young adults despite the advent of EZH2 inhibitor tazemetostat. METHODS: In order to realise consistently ...

    • Future Directions in the Treatment of Osteosarcoma. 

      Smrke, A; Anderson, PM; Gulia, A; Gennatas, S; Huang, PH; et al. (MDPI, 2021-01-15)
      Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy ...

    • Immunotherapy of sarcomas with modified T cells. 

      Mahalingam, P; Julve, M; Huang, P; Furness, AJS; Pollack, SM; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-07-01)
      PURPOSE OF REVIEW: To summarize the development of modified T-cell therapies in sarcomas and discuss relevant published and ongoing clinical trials to date. RECENT FINDINGS: Numerous clinical trials are underway evaluating ...

    • Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? 

      Cojocaru, E; Wilding, C; Engelman, B; Huang, P; Jones, RL (Springer Science and Business Media LLC, 2020-03-01)
      <jats:title>Abstract</jats:title><jats:p>Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known to be resistant to systemic cytotoxic chemotherapy ...

    • Molecular profiling in desmoplastic small round cell tumours. 

      Tam, YB; Jones, RL; Huang, PH (PERGAMON-ELSEVIER SCIENCE LTD, 2023-04-01)
      Desmoplastic small round cell tumour (DSRCT) is an ultra-rare soft tissue sarcoma that is characterised by aggressive disease and dismal patient outcomes. Despite multi-modal therapy, prognosis remains poor and there are ...

    • Molecular subtypes of leiomyosarcoma: Moving toward a consensus 

      Burns, J; Jones, RL; Huang, PH (Wiley, 2022-12-01)

    • Next-generation sequencing for the management of sarcomas with no known driver mutations. 

      Vyse, S; Thway, K; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2021-07-01)
      PURPOSE OF REVIEW: Next-generation sequencing (NGS) has enabled fast, high-throughput nucleotide sequencing and has begun to be implemented into clinical practice for genomic-guided precision medicine in various cancer ...

    • Novel therapeutic approaches in chondrosarcoma. 

      Polychronidou, G; Karavasilis, V; Pollack, SM; Huang, PH; Lee, A; et al. (FUTURE MEDICINE LTD, 2017-03-01)
      Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally ...

    • Olaratumab in soft tissue sarcoma - Current status and future perspectives. 

      Antoniou, G; Lee, ATJ; Huang, PH; Jones, RL (ELSEVIER SCI LTD, 2018-03-01)
      Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented ...

    • Optimal Clinical Management and the Molecular Biology of Angiosarcomas. 

      Chen, TW-W; Burns, J; Jones, RL; Huang, PH (MDPI, 2020-11-10)
      Angiosarcomas comprise less than 3% of all soft tissue sarcomas but have a poor prognosis. Most angiosarcomas occur without obvious risk factors but secondary angiosarcoma could arise after radiotherapy or chronic lymphedema. ...

    • Pazopanib in advanced soft tissue sarcomas. 

      Lee, ATJ; Jones, RL; Huang, PH (NATURE PUBLISHING GROUP, 2019-05-17)
      Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular ...

    • Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. 

      Chamberlain, FE; Wilding, C; Jones, RL; Huang, P (TAYLOR & FRANCIS LTD, 2019-07-03)
      Introduction: Liposarcomas (LPS) are a heterogeneous group of adipocytic soft tissue sarcomas with limited treatment options in the advanced/metastatic setting. Pazopanib is a multi-target tyrosine kinase inhibitor (TKI) ...

    • Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. 

      Chamberlain, F; Benson, C; Thway, K; Huang, P; Jones, RL; et al. (FUTURE MEDICINE LTD, 2021-04-21)
      Liposarcomas are rare tumors arising from adipocytic tissue and accounting for approximately 15-20% of all soft tissue sarcomas. Liposarcoma can be further classified into histopathological subtypes with variable ...

    • Phase III Soft Tissue Sarcoma Trials: Success or Failure? 

      Lee, ATJ; Pollack, SM; Huang, P; Jones, RL (SPRINGER, 2017-03-01)
      Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II ...